Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis by Pruimboom, W.M. (Wanda) et al.
Pergamon 
Inr. J. Immunopharmnc., Vol. I?, No. 5, pp. 375-384, 1995 
Elsevier Science Ltd 
Copyright 0 1995 International Society for Immunopharmacology 
Printed in Great Britain. All rights reserved 
0192-0561195 $9.50 + .OO 
0192-0561(95)00015-1 
LEVELS OF SOLUBLE INTERCELLULAR ADHESION MOLECULE 1, 
EICOSANOIDS AND CYTOKINES IN ASCITES OF PATIENTS WITH LIVER 
CIRRHOSIS, PERITONEAL CANCER AND SPONTANEOUS BACTERIAL 
PERITONITIS 
W. M. PRUIMBOOM,* D. J. BAC,’ A. P. M. VAN DIJK,* I. M. GARRELDS,* C. J. A. M. TAK,* 
I. L. BONTA,* J. H. P. WILSON+ and F. J. ZIJLSTRA* 
*Department of Pharmacology, Erasmus University, P. 0. Box 1738,300O DR Rotterdam, The Netherlands; and 
‘Department of Internal Medicine II, University Hospital Dijkzigt Rotterdam, The Netherlands 
(Received infinal form 3 January 1995) 
Abstract-The levels of the eicosanoids leukotriene B,, prostaglandin E,, prostacycline and thromboxane B,, the 
cytokines interleukin- 1 p, interleukin-6 and tumour necrosis factor-a and soluble intercellular adhesion molecule 1 
were measured in ascites and plasma samples of patients with liver cirrhosis (53), peritoneal cancer (26) and 
spontaneous bacterial peritonitis (10) to assess their value as a possible diagnostic and prognostic parameter in the 
course of the disease. Soluble intercellular adhesion molecule 1, of the eicosanoids prostaglandin E, and leukotriene 
B,, and the protein concentration in ascites were all significantly elevated in ascites of patients with peritoneal 
cancer in comparison to ascites of patients with liver cirrhosis. In ascites of patients with spontaneous bacterial 
infection interleukin-6 concentration was significantly elevated and the protein concentration was significantly 
lower in comparison to the other two groups. None of these parameters, however, seems to be of practical use as a 
diagnostic parameter, as there is an overlap between all the levels of these mediators in ascites of liver cirrhosis, 
peritoneal cancer and spontaneous bacterial peritonitis group. Soluble intercellular adhesion molecule 1 levels 
were much higher in plasma than in ascites, in contrast to interleukin-6 levels which were much higher in ascites 
than in plasma. Soluble intercellular adhesion molecule 1 in ascites correlated with soluble intercellular adhesion 
molecule 1 in plasma (r = 0.6926, P = 0.000 1). Soluble intercellular adhesion molecule 1, interleukin-6 and the 
number of polymorphonuclear cells in peritoneal fluid correlated during episodes of infection in patients with a 
peritonitis. For this reason soluble intercellular adhesion molecule 1 and interleukin-6 could be of prognostic value 
for patients with peritonitis. 
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Ascites is the accumulation of fluid in the peritoneal inflammatory mediators or products of inflammation 
cavity. The main causes of ascites are liver cirrhosis, to determine whether the different causes of ascites 
malignancies involving the peritoneum and inflam- were associated with specific patterns of inflam- 
matory processes. Early diagnosis of the probable cause matory mediators in ascites. Based on prior work in 
of the ascites is useful for guiding further investigation which we characterized production of inflammatory 
and treatment (Bat et al., 1993a). Ascites may be mediators by human peritoneal macrophages (hp-M$; 
complicated by bacterial infection, a condition known Pruimboom et al., 1994) we measured arachidonic 
as spontaneous bacterial peritonitis (SBP). SBP has a acid products, several pro-inflammatory cytokines, and 
high mortality unless diagnosed and treated at an early a soluble form of an adhesion molecule. The lipoxy- 
stage (Bat et al., 1993b). Ascites of all causes contain genase product leukotriene B, (LTB,; Lewis & 
inflammatory cells, mainly macrophages (Me), which Austen, 1984) and the cyclooxygenase products 
produce inflammatory mediators. As the pattern of prostaglandin E, (PGE,), thromboxane A, (TXA,) and 
mediators produced by inflammatory cells depends in prostacycline [PGI, detected as 6-keto prostaglandin F,= 
part on the stimulus and on the stage of inflammation, (6kPGF& Goldyne, 19871 were measured as these 
we decided to measure in ascites a wide variety of are products of hp-Mjr (Pruimboom et al., 1994). 
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We also measured the pro-inflammatory cytokines 
interleukin- 1 p (IL- 1 p), IL-6 and tumour necrosis factor- 
CL (TNF-a, Arai et al., 1990; Oppenheim et al., 1991) 
which are also produced by hp-MQ, (Pruimboom et al., 
1994). 
In addition, we measured the soluble intercellular 
adhesion molecule 1 (sICAM-1). ICAM- plays a 
crucial role in the adhesion and migration of inflam- 
matory cells, and is a single-chain membrane-bound 
glycoprotein (Springer, 1990) which is expressed on 
endothelial and other cells (Springer, 1990; Dustin et 
al., 1986; Temponi et al., 1988). Expression of 
ICAM- is up-regulated by the cytokines IL-l, TNF-a 
and interferon-gamma (IFN-y) (Dustin et al., 1986; 
1986; Temponi et al., 1988; Pober et al., 1986; 
Beekhuizen et al., 1991) and also by the chemo- 
attractants LTB, and C5a (Pattaroyo, 1989). Expression 
of ICAM- on tissue leads to the release of a soluble 
form into the circulation. The biological function of 
this soluble form of ICAM- is not yet clear and little 
is known about the relation between expression of 
ICAM- 1 on tissue and its soluble form. Soluble isoforms 
of adhesion molecules can be found in the circulation 
of normal humans (Rothlein et al., 1991). 
Although there are publications on IL-6 and TNF-a 
in ascites, especially during SBP (Andus et al., 1992; 
Pelletier et al., 1992; Propst et al., 1993; Deviere 
et al., 1991) we are not aware of any reports on ascitic 
eicosanoid and ascitic sICAM-1 levels. Soluble 
ICAM- in plasma or serum (Rothlein ei al., 199 1; 
Adams et al., 1992; Banks et al., 1993; Stikakis et al., 
1993; Sharief et al., 1992; Harning et al., 1991; 
Nouri-Aria et al., 1993) and the cytokines IL-l, IL-6 
and TNF-a in plasma, serum or ascites (Andus et al., 
1992; Pelletier et al., 1992; Sharief et al., 1992; 
Khoruts et al., 1991; Byl et al., 1993; Tilg et al., 1992; 
McClain et al., 1986; Felver et al., 1990) have been 
found to be elevated in patients with different 
diseases including malignancies and liver cirrhosis. 
Therefore we measured the levels of sICAM-1, the 
representative eicosanoids LTB,, PGE,, PGI, and TXB, 
and the pro-inflammatory cytokines IL-lj3, IL-6 and 
TNF-a in ascites of patients with liver cirrhosis, 
peritoneal cancer and SBP to increase our under- 
standing of inflammatory mediators involved in 
peritoneal inflammation, to determine whether these 
mediators showed a specific disease-related pattern and 
whether this pattern could be of diagnostic and 
prognostic value. 
Simultaneously, we measured the same parameters 
in blood samples of these patients to determine whether 
there was a close correlation between ascites and plasma 
values. 
EXPERIMENTAL PROCEDURES 
Patients 
Eighty-nine ascites samples were obtained. Some 
patients were drained several times during the period 
in which samples were collected. There was usually a 
period of several weeks between samples (a total of 
63 patients were drained). These samples were divided 
into three groups: the liver cirrhosis group [number of 
samples = 53, sex (M/F) = 33120, age (range) = 
58 (27-82)], the peritoneal cancer group [number of 
samples = 26, sex (M/F) = 18/8, age (range) = 
61 (37-81)] and the SBP group [number of sam- 
ples = 10, sex (M/F) = 713, age (range) = 48 (22-59)]. 
A patient with ascites was classified as having SBP 
if the number of polymorphonuclear cells (PMN) was 
higher then 0.25 x lo9 cells/l in the ascites and the 
bacterial culture of the ascitic fluid was positive, or in 
case the culture was negative, the PMN count in the 
ascites should be higher then 0.5 x lo9 cellsil (Bat et 
al., 1993a). A patient with renal failure on continuous 
ambulatory peritoneal dialysis (CAPD) was classified 
as having a peritonitis if the number of PMN was higher 
then 0.10 x 1 O9 cells/I in the dialysates and the bacterial 
culture was positive (Vas, 1989). 
In the liver cirrhosis group there were 29 samples 
obtained from patients with alcoholic liver cirrhosis, 
13 samples from patients with hepatitis B or C virus 
induced cirrhosis, three samples from patients with 
primary biliary cirrhosis or sclerosing cholangitis, five 
samples from patients with Budd Chiari and three 
samples from patients with other diseases. 
Of the malignancy-related ascites group all patients 
had metastized disease. Eight samples were obtained 
from patients with colon carcinoma, seven samples from 
patients with pancreatic carcinoma, three samples from 
patients with liver carcinoma, two samples from patients 
with peritoneal mesothelioma, two samples from 
patients with gastric carcinoma, one sample from a 
patient with lung carcinoma, one sample from a patient 
with a sarcoma and two samples from patients with an 
unknown primary source. 
In the SBP group four samples were obtained from 
a patient with hepatitis B virus-induced cirrhosis, and 
this patient had a Staphylococcus epidermidis infection 
in the ascites (PMN number varied between 0.5 x IO9 
and 4.2 x 1 O9 cells/l), three samples were obtained from 
a patient with a pancreas carcinoma and a portal vein 
thrombosis, and this patient had a Klebsiella infection 
in the ascites (PMN number varied between 0.6 x lo9 
and 15.6 x 1 O9 cells/l), two samples were obtained from 
patients with liver cirrhosis, one of these patients had 
an Escherichia coli infection in the ascites (4.3 x 10’ 
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Fig. 1. (A) Soluble ICAM- 1 concentration (ng/ml) in ascites of 
patients with ascites due to liver cirrhosis (liver, n = 53), 
peritoneal cancer (cancer, n = 26) and SBP (infection, n = 10). 
(B) Interleukin-6 concentration (@ml) in ascites of patients 
with ascites due to liver cirrhosis (liver, n = 53), peritoneal 
cancer (cancer, n = 26) and SBP (infection,n = IO). (C) Protein 
concentration (mg/ml) in ascites of patients with ascites due to 
liver cirrhosis (liver, n = 46), peritoneal cancer (cancer, II = 25) 
and SBP (infection, n = 7). *Significantly higher than the 
other two groups (WO.05); **Significantly lower than the 
other two groups. 
PMN/l), the other patient had a Streptococcus mitis 
infection in the blood, the ascitic culture of this patient 
was negative (7.8 x lo9 PMN/l in ascites). One sample 
was obtained from a patient with an acute liver failure 
and an Escherichia coli infection in the ascites 
(10.5 x lo9 PMN/l). 
In 34 of these patients with ascites, blood 
(24 samples from the liver cirrhosis group, six samples 
from the cancer group and four samples from the SBP 
group) was collected in EDTA-tubes on the same day 
or the day after ascites drainage. Blood was also 
obtained from 17 healthy volunteers [sex (M/F) = 
12/5, age (range) = 29 (23+0)]. 
From two patients [sex (M/F) = l/l, age (range) = 49 
(41-57)] with renal failure on continuous ambulatory 
peritoneal dialysis (CAPD), the drained dialysates were 
collected during and after an episode of peritoneal 
bacterial infection. The first CAPD patient had a 
Klebsiella infection. The number of PMN varied 
between 0.1 x lo9 and 3.8 x lo9 PMN/l. The second 
CAPD patient had Enterococcus faecalis infection. 
The number of PMN varied between 0.2 x lo9 and 
1.4 x lo9 PMN/I. 
Assays 
The ascites, dialysates and blood were centrifuged 
at 15OOg directly after withdrawal. The centritiged 
ascites, dialysates and plasma were stored at -80°C until 
they were analysed. Soluble ICAM-1, TNF-(r, IL-l/3 
and IL-6 were determined in the centrifuged ascites and 
plasma using commercially available ELISA kits 
(sICAM-1, British Biotechnology Products, U.K., 
sensitivity 2.5 ng/ml; TNF-cc, Eurogenetics, U.S.A., 
sensitivity 10 pg/ml; IL-lb, Eurogenetics, U.S.A., 
sensitivity 2 pg/ml; IL-6, Hycult, The Netherlands, 
sensitivity 2 pg/ml). 
LTB,, PGE,, 6kPGF,a and TXB, were determined 
by radioimmunoassays (Antibodies, Advanced Mag- 
netics, U.S.A., ‘H-Antigen, Amersham, U.K.; standards, 
Sigma, U.S.A.) in centrifuged ascites and plasma which 
were passed through Sep Pak C,, cartridges (Water 
Assoc., U.S.A.). 
In the dialysates only sICAM-1 and IL-6 were 
determined. Protein concentrations in the ascites and 
plasma were determined using the pyrogallol-red- 
molybdate(IV) method (Instruchemie, The Nether- 
lands). 
Statistical analysis 
Data are expressed as the mean f S.E.M. Data were 
statistically analysed with ANOVA followed by 
Student’s t-test. The correlations were determined by 
the Pearson Correlation test. Data were considered 
significant when PcO.05. 
RESULTS 
Soluble ICAM-1, cytokine and eicosanoid concentra- 
tions in ascites 
The soluble ICAM- concentration was significantly 
elevated in ascites of patients with peritoneal cancer 
(385 f 66 @ml, n = 26) compared to the conceritration 
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Table I. Eicosanoid concentration in ascites of patients with liver cirrhosis, 
peritoneal cancer and SBP 
Liver cirrhosis Peritoneal cancer SBP 
Eicosanoids (n) (n) (n) 
LTB, 21 *5.4 193 i67** nd* 
(pg/mB (47) (26) (10) 
PGE, 27 % 3.2* 122 i 27*** 79 f. 20.7 
(pg/mB (47) (26) (10) 
6kPGF,a 145 * 62 359 i 110**** 113*38 
(pgiml) (47) (26) (10) 
TXBz 57*8.1 70 * 9.4 53 f. 3.2 
(pg/ml) (46) (26) (8) 
Data are means * S.E.M. 
nd, Not detectable; n, number of samples. 
*Significantly lower than the other two groups (PcO.05). 
**Significantly higher than the other two groups (PcO.05). 
***Significantly higher than the liver cirrhosis group (PcO.05). 
****Significantly higher than the SBP group (PcO.05). 
Table 2. Soluble ICAM-1, cytokine and eicosanoid concentration in plasma of patients 
with liver cirrhosis, peritoneal cancer and SBP and in plasma of controls 
Liver cirrhosis Peritoneal cancer SBP Plasma control 
Mediators (n) (a) (n) (n) 
sICAM- 1 781 i 141 781 i367 1204*271 228 f 24* 
(ng/ml) (24) (5) (3) (17) 
IL-6 1191 i358 420*215 1736*394 nd* 
(pg/ml) (24) (6) (4) (17) 
IL-1p nd nd nd nd 
(pgiml) (17) (6) (4) (17) 
TNF-tJt nd nd nd 
(pg/mB (YY) (6) (4) (17) 
LTB, 22 * 16.3 14 i 14.1 54 + 54.6 nd 
(pg/ml) (23) (6) (4) (17) 
PGE, 67 f 21.1 68 f 32.1 52 f 48.0 70 + 13.0 
(pg/mB (23) (6) (4) (16) 
6kPGF,a 104 * 67.4 14 * 14.3 6.7 * 4.7 8.8 f 1.4 
(pg/mB (23) (6) (4) (16) 
TXB, 256 i 126 141 f 51 127*32 153 f 67 
(pg/mB (17) (6) (2) (14) 
*Significantly lower than the three patient groups (P<O.OS). 
Data are means f S.E.M. 
n, number of samples. 
nd. Not detectable. 
of sICAM-1 in ascitic fluid of patients with liver 
cirrhosis (15 1 f 16 ng/ml, n = 53, P = 0.0000) and SBP 
(215 f 27 ng/ml, n = 10, P = 0.0284). There was no 
significant difference between the concentrations in 
ascites from patients with liver cirrhosis and SBP 
(Fig. 1A). 
The IL-6 concentration was significantly elevated 
in ascites of patients with SBP (103 f 24 @ml, n = 10) 
compared to the concentration of IL-6 in ascites of 
patients with liver cirrhosis (12 f 1.8 @ml, n = 53, 
P = 0.0000) and peritoneal cancer (24 f 5.7 ng/ml, 
n = 26, P = 0.0000; Fig. 1B). 
The ascites protein concentration was significantly 
lower in SBP (10 f 1.6 mg/ml, n = 7, P = 0.0104) than 
in the liver cirrhosis group (26 f 2.4 mg/ml, n = 46) and 
peritoneal cancer group (44 f 2.6 mg/ml, n = 25, 
P = 0.0000). Ascites protein levels are significantly 
higher (P = 0.0000) in peritoneal cancer than in the other 
two groups (Fig. 1C). 
Of the eicosanoids, LTB, and PGE, concentrations 
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Table 3. sICAM- 1, cytokine and eicosanoid concentration in 
ascites and plasma of patients (grouped all together) with 
liver cirrhosis, peritoneal cancerand SBP 
Mediators Ascites (n) 
slCAM-1 227 f 24 
ng/ml (89) 
IL-6 26 f 4.4** 
@ml (89) 
IL-lb 10 ??2.7 
pg/ml (59) 
TNF-a 65 * 24.4:’ 
pglml (78) 
LTB, 72 * 22.1 
pgiml (84) 
PGE, 63 f 10.0 
pg/ml (84) 
6kPGF,a 206 * 50 
pg/ml (84) 
TXB, 61 + 5.5 
pg/ml (81) 
Data are means ??S.E.M. 
Plasma (n) 
820 f 122* 
(32) 
1 ??0.3 
(34) 
(Z) 
(ii) 
25 * 13.0 
(33) 
65 f 16.4 
(33) 
76 & 41.3 
(33) 
218 f 86.2 
(25) 
nd, not detectable; n, number of samples. 
*Significantly higher than the ascites values (P<O.OS). 
**Significantly higher than the plasma values (P<O.O5). 
were significantly higher in ascites of patients with 
peritoneal cancer (n = 26) than in the liver cirrhosis 
group (n = 47), and ascites LTB, and 6kPGF,a 
concentrations of peritoneal cancer were significantly 
increased in comparison to SBP (n = 10, Table 1). The 
LTB, concentration in ascites of patients with SBP, and 
the PGE, concentration in ascites of patients with liver 
cirrhosis were significantly lower in comparison with 
the other two groups. 
Soluble ICAM-1, cytokine and eicosanoid concentra- 
tions in piasma 
In Table 2 the plasma levels of sICAM-1, cytokine 
and eicosanoid concentrations per patient group and 
controls were compared. No significant differences were 
seen between the three patient groups. Soluble ICAM- 1 
and IL-6 concentrations in plasma of the patients were 
significantly elevated in comparison to the controls. 
IL- 1 l3 and TNF-a were not detectable in plasma of 
patients; IL-lB, IL-6, TNF-a and LTB, were not 
detectable in control plasma. 
Comparison between the sICAM-1, cytokine and eico- 
sanoid concentrations in ascites and plasma 
As we had only a small number of plasma samples 
from the peritoneal cancer and SBP groups and there 
were no significant differences between the plasma 
levels of the three patient groups, all the plasma samples 
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Fig. 2. Correlation between soluble ICAM- in ascites and 
plasma of patients with ascites due to liver cirrhosis, peritoneal 
cancer and SBP (r = 0.6926, P = 0.0001, n = 27). 
of patients were compared with the ascites samples, 
without subdivision, as calculated and shown in Table 3. 
There were differences between plasma and ascites 
values: sICAM-1 concentration was much higher in 
plasma, while IL-6 and TNF-a concentrations were 
higher in ascites (Table 3). 
There was a good relation between ascites sICAM-1 
and plasma sICAM-1 (V = 0.6926, P = 0.0001, n = 27, 
Fig. 2); for the other metabolites there was no 
correlation. 
Soluble ICAM-I and IL-6 concentrations during 
peritonitis 
In two patients with SBP, the ascites was drained 
several times (patient 1: five times, days 0, 25, 28, 32, 
38, and patient 2: four times, days 0, 6, 18, 24) over 
5-6 weeks. For both these patients sICAM-1 and IL-6 
concentrations in ascites changed during this period: 
patient 1 had no SBP on the first day (day 0) of drainage 
(negative culture, 0.1 x 1 O9 PMIW). The sICAM- 1 and 
IL-6 concentrations in the ascites were low (77 ng/ml 
sICAM-1 and 1 @ml IL-6). On day 25 the patient 
had a subtotal hepatic resection. After this operation 
the number of PMN (1.7 x lo9 PMNIl), sICAM-1 
(190 ng/ml) and IL-6 (72 ng/ml) had increased in the 
ascites. A Staphylococcus epidermidis infection was 
diagnosed on day 28 in the ascites (0.5 x lo9 PMNIl, 
242 ng/ml sICAM-1, 56 ng/ml IL-6). During the 
peritonitis sICAM-1 and IL-6 concentrations peaked at 
day 32 (316 ng/ml sICAM-I, 119 q/ml IL-6,4.2 x lo9 
PMN/l). Antibiotics were given after day 32, after which 
the sICAM-1 and IL-6 concentrations decreased 
(195 ng/ml sICAM, 79 ng/ml IL-6, 2.2 x lo9 PMN/l, 
Fig. 3A). 
Patient 2 had a Klebsiella peritonitis on the first day 
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Fig. 3. Soluble ICAMOI (0) and IL-6 (m) concentrations (ng/ml) in ascites of two patients with SBP. (A) Patient 1 had no SBP on 
day 0 of drainage. The patient was operated on day 25, and a Sfaphylococcus epidermidis infection started after this operation. 
Antibiotics were given after day 32. (B) Patient 2 had a SBP on the first day of drainage (Klebsiellu infection). Antibiotics were 
given for several weeks. At day 24 the patient was free of infection. 
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Fig. 4. Soluble ICAM- (0) and IL-6 (m) concentrations (ng/mI) in drained dialysates oftwo CAPD patients during an episode of 
peritoneal infection. (A) Patient 3 had a peritonitis (Klebsiella) on day 0 and no antibiotics had yet been given. On day 1 antibiotics 
were given. On day 13 the patient was free of infection. (B) Patient 4 had a peritonitis (Enteroccusfoecolis) on day 0 and no 
antibiotics had yet been given. On day 12 the patient was free of infection. 
Patient 4 
of drainage. In the ascites of this patient the SEAM-I 
and IL-6 concentrations and the PMN number were high 
(35 1 ng/ml sICAM-I,48 @ml IL-6, 15.6 x 1 O9 PMN/I). 
Antibiotics were given for several weeks and 
the sICAM-1 concentration decreased to a low level 
(56 @ml). IL-6 concentration slightly increased (day 
6,60 @ml), but then also decreased to a very low level 
(0.3 ng/ml). At the same time the number of PMN 
decreased (3.4 x lop PMN/l on day 6, 0.6 x lo9 PMNil 
on day 18). At the last drainage the bacterial culture of 
the ascites was negative and the number of PMN had 
further decreased (0.5 x lo9 PMN/l; Fig. 3B). 
The ICAM-I and IL-6 concentrations were also 
measured in drained dialysates of two CAPD patients 
during an episode of peritoneal infection (patient 3: four 
times, days 0, 1, 8, 13) and patient 4: six times, days 0, 
3, 6, 7, 10, 12). Patient 3 had an untreated bacterial 
infection on day 0 (Klebsiella, 1.4 x lo9 PMN/l), the 
sICAM-1 concentration was 3 ng/ml and the IL-6 
concentration 80 @ml. On day 1 antibiotics were given 
and the IL-6 concentration decreased (66 @ml), and 
the sICAM-1 concentration (6 ng/ml) and the number 
of PMN (3.8 x lo9 PMN/l) increased. On day 8 the 
sICAM-1 concentration had decreased only slightly, but 
the IL-6 concentration (3 &ml) and the number of PMN 
(0.1 x 1 O9 PMNII) had decreased. On day 13 the patient 
was free of infection (negative culture, CO.1 x IO9 
PMN/I), sICAM-1 was not detectable and the IL-6 
concentration stayed low (3 ng/ml; Fig. 4A). 
Patient 4 had a bacterial infection on day 0 
(Enterococcus faecalis, 1.4 x 1 O9 PMN/l) and before 
antibiotics were given, the sICAM- 1 concentration was 
21 ng/ml and the IL-6 concentration 12 ng/ml. On day 
3 after antibiotics were given, the IL-6 concentration 
increased slightly (13 ng/ml), but sICAM- 1 concen- 
tration (9 ng/ml) and also the number of PMNs in the 
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dialysates (0.8 x lo9 PMN/l) decreased. Between days 
6 and 10 the infection was still present, but the concen- 
tration of sICAM-1 and IL-6 and the number of PMN 
decreased (day 6: 0.9 r&ml sICAM-1, 0.8 ng/ml IL-6, 
0.5 x 1 O9 PMN/l; day 7: 0 r&ml sICAM-I,2 ng/ml IL-6, 
0.2 x lo9 PMN/l; day 10: 0 ng/ml sICAM-1, 0.9 @ml 
IL-6, 0.1 x lo9 PMNII). On day 12 the patient was free 
of infection (negative culture, PMN ~0.1 x log), 
sICAM-1 was not detectable and the IL-6 concentration 
(0.8 ng/ml) was also low (Fig. 4B). 
The correlation between sICAM-1, IL-6 and the 
number of PMN in the ascites and the drained dialysates 
in those patients with a peritonitis was for sICAM-1 
and PMN 0.7201 (P = 0.0002), for IL-6 and PMN 0.4454 
(P = 0.0378) and for sICAM-1 and IL-6 0.4800 
(P = 0.0238). 
DISCUSSION 
The present study shows that there are significant 
differences in the concentrations and patterns of 
inflammatory products in ascites due to different 
disorders. Soluble ICAM-1, the eicosanoids PGE, and 
LTB, all clearly differentiated between peritoneal cancer 
and liver cirrhosis: these metabolites were all higher in 
ascites of patients with peritoneal cancer. Ascitic 
sICAM- 1 and ascitic IL-6 also increased during episodes 
of peritoneal infection in two patients with SBP as well 
as in infected dialysates of two CAPD patients. 
Soluble ICAM- levels were much higher in plasma 
than in ascites, in contrast to IL-6 levels which were 
much higher in ascites than in plasma. Soluble ICAM- 
in ascites of all the patients correlated with sICAM-1 
in plasma of these patients. The sICAM-1 levels in 
plasma of patients were significantly higher than the 
plasma levels of the controls. The cytokines IL-l B and 
TNF-a were low or not detectable in ascites or plasma 
of patients with liver cirrhosis, peritoneal cancer or SBP. 
Soluble ICAM- concentration in ascites and plasma 
Although there were significant differences in 
concentrations of sICAM-1 in ascites, in the different 
disorders plasma levels of sICAM-1 were not 
significantly different, probably due to the small number 
of plasma samples in the peritoneal cancer group and 
the SBP group. Other studies showed that sICAM-1 
levels were elevated in sera of patients with different 
type of diseases in comparison to controls (Rothlein et 
al., 1991; Stikakis et al., 1993; Sharief et al., 1992) 
including acute liver disease (chronic hepatic C virus 
infection, Nouri-Ariaet al., 1993), chronic liver diseases 
(primary biliary cirrhosis and primary sclerosing 
cholangitis, Adams et al., 1992) and patients with 
different forms of cancer (Banks et al., 1993; Haming 
et al., 199 1). Soluble ICAM- 1 is probably released more 
to the bloodstream circulation than locally within the 
peritoneal cavity as the sICAM-1 levels in plasma of 
all the patients was significantly higher than levels in 
ascites of all the patients. Adhesion to and penetration 
through the vascular endothelium is a mandatory step 
for leucocyte migration and accumulation at sites of 
inflammation. De novo or up-regulated expression of 
adhesion molecules on sinusoidal lining cells in 
inflamed liver biopsy specimens indicates that these 
endothelial cells actively modulate their phenotype in 
response to environmental factors, thus playing a key 
role in the recruitment of leucocytes in acute and chronic 
liver inflammation (Volpes et al., 1992) and probably 
leading to the release of ICAM- locally. Malignant 
melanomas are usually surrounded by a heavy 
inflammatory infiltrate; the inflammatory cells ofien 
express activation-associated markers (Raltkiaer et al., 
1987) and the malignant melanomas express ICAM- 
(Hansen et al., 1991). An explanation for the significant 
differences of sICAM- 1 concentration in ascites of the 
different groups in our study could be that cancer cells 
are also a source of sICAM-1. A study showed that an 
unstimulated human melanoma cell line expressed 
ICAM- on the cell surface but did not release 
significant levels of sICAM-1. Stimulation with TNF-a, 
IL-l and IFN-y, but not IL-6, then caused the release of 
sICAM-1. The same group showed in the same 
publication that in nude mouse models bearing S.C. 
human melanoma turnours, the serum contained human 
sICAM-1 (Giavazzi et al., 1992). These two studies 
show clearly that only the cancer cells in these models 
could have been the source of the soluble form of 
ICAM-1. In humans, cancer cells are probably an 
important source for the release of sICAM-1 locally 
into the peritoneal cavity. Assuming that cancer cells 
are a source of sICAM-1, this may provide cancer cells 
with additional escape mechanisms, e.g. ineffective 
recognition of cell surface ICAM- by cytotoxic 
lymphocytes or blocking immune recognition by 
blocking the ligand for ICAM-1, lymphocyte-function- 
associated antigen 1 (LFA-l), on the leucocytes 
(Springer, 1990; Rothlein et al., 1986). 
All our patients with peritoneal cancer had high 
levels of sICAM-1 in the ascites. As all these patients 
have late stage cancer, it was not possible to correlate 
the disease progression of these patients with the 
sICAM- 1 level in the ascites or plasma of these patients. 
Other studies did show that the levels of sICAM-1 in 
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humans correlated with liver metastasis in a variety of 
turnours, and with disease progression in melanoma 
cells (Banks et al., 1993; Harning et al., 1991). 
IL-l, IL-6 and TNF-a concentrations in ascites and 
plasma 
In previous studies we isolated M@I from ascitic fluid 
of patients with liver cirrhosis. These MQ had a high 
IL-6 production capacity (Pruimboom et al., 1994). The 
IL-6 levels in the ascites of the patients used for this 
study were always much higher in the peritoneal cavity 
than in the plasma, indicating that IL-6 was produced 
locally in the peritoneal cavity by MQ. Endothelial cells 
are also able to produce IL-6 (Aarden et al., 199 1; Jirik 
et al., 1989). IL-lfl and TNF-a were hardly detectable 
in ascites or plasma of patients with liver cirrhosis, 
peritoneal cancer and PBS. Other reports, however, 
show that besides elevated IL-6 levels, elevated IL-I 
and TNF-a plasma levels were found in patients with 
ascites caused by liver diseases, in comparison to 
controls (Khoruts et al., 199 1; Tilg et al., 1992). In SBP 
patients, in comparison to non-infected patients, 
elevated TNF-a levels in ascites (Deviere et al., 1991) 
and plasma (By1 et al., 1993) were also found. Similarly 
to our results, one other report also described significant 
elevated IL-6, but not IL-l or T’NF-a levels in ascites 
and serum of SBP patients (Propst et al., 1993). 
Besides MI$I and endothelium, tumour cells should 
also be considered as potential sources of IL-6. Some 
tumour cells have been shown to produce IL-6 (Heinrich 
et al., 1990; Kawano et al., 1988). IL-6 is a potent 
growth factor for myeloma/plasmacytoma cells and its 
deregulated expression may be involved in the 
oncogenesis of human multiple myelomas (Kishomoto, 
1989). In this way IL-6 can be involved in the growth 
pattern of malignancy. 
The liver is an important site of synthesis and is the 
main clearance organ of circulating cytokines. The rapid 
hepatic clearance of circulating cytokines may normally 
constitute an important mechanism limiting the 
systemic action of cytokines. Lack of hepatic clearance 
may be one reason for disturbances of the immune 
system in patients with hepatic cirrhosis (Andus et al., 
1991) and probably also in patients with liver metastasis. 
IL-6 is important in liver diseases, as it induces acute- 
phase protein synthesis, particularly fibrinogen 
production, in hepatocytes (Kishomoto, 1989). The high 
IL-6 production during the bacterial infection is 
probably a direct effect of the bacteria on the 
macrophages in the peritoneum: lipopolysaccharide 
(LPS), a bacterial membrane component, is known to 
be one of the most potent stimuli of M$ (Lynn & 
Golenbock, 1992). Increasing LPS concentrations 
increase the IL-6 production capacity of human 
peritoneal M@ in vitro (Pruimboom et al., 1994). 
Correlation between IL-6 and sICAM- 1 
The high sICAM-1 and IL-6 levels and low IL-l p 
and TNF-a levels in the patients with ascites could 
indicate that there is a connection between IL-6 and 
sICAM- 1: IL-6 could induce ICAM- expression and 
also the release of the soluble form. In an auto-immune 
mouse model ICAM- 1 was newly induced in the hepatic 
sinusoids of controls by intravenous injection of 
recombinant mouse IL-6, and elevated production of 
IL-6 by hepatic mononuclear cells also correlated with 
this ICAM- expression (Ohteki et al., 1993). However, 
incubation of cultured monolayers of human endothelial 
cells with IL-6 did not affect their adhesiveness for 
human monocytes (Beekhuizen et al., 1991). IL-I alp, 
TNF-a and IFNq, but not IL-6, increase the 
permeability of human endothelial cells in vitro (Burke- 
Gaffney & Keenan, 1993). 
It has not been shown previously that both sICAM-1 
and IL-6 levels in ascites of patients with SBP and in 
the dialysis fluid of CAPD patients with SBP correlated 
with episodes of infection. sICAM-I and IL-6 levels 
were high when the patients had an infection, decreased 
when antibiotics were given and were hardly detectable 
when the patients were free of infection. 
Eicosanoids in ascites and plasma 
It is not clear why LTB, production is much higher 
in ascites of the peritoneal cancer group than in the liver 
cirrhosis group. It is likely that cancer cells in the 
peritoneal cancer group activate the inflammatory cells 
to produce LTB,. This elevation may in turn stimulate 
ICAM- expression (Holt et al., 1993). 
The release of the vasodilating agents PGE, and PGI, 
(Goldyne, 1987) could act as mediators involved in the 
induction of ascites (Hamilton et al., 1982). In patients 
with a liver disease, endothelial cells, macrophages and 
hepatocytes or the disability of the liver to clear these 
vasodilators (Keppler et al., 1985) could be responsible 
for the PGE, and PGI, production. In patients with 
cancer, the cancer cells themselves could also be 
responsible for the high concentration of the PG in 
ascites. A number of experimentally induced tumours 
in animals, as well as those occurring naturally in 
humans, have been found to produce high amounts of 
PG, in particular PGE, (Strelkov et al., 1989; Husby et 
al., 1977). 
In conclusion, the levels of sICAM-1, the eico- 
sanoids LTB, and PGE, and the protein concentration 
in ascites are parameters which showed a specific 
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disease-related pattern; however, for diagnostic use they sICAM-1 and IL-6 seem to be parameters which could 
may not be suitable as all the parameters of the three be used in the future to monitor patients with SBP. 
different patient groups overlapped. However, as 
sICAM-1 levels in ascites correlated with sICAM-1 
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